Bal Pharma

₹82.52As of Sun 8 Nov 2026, 12:00 UTC

NSE:BALPHARMAHealthcare

Country India

PE (Fwd) 19.80

TSR 10Y CAGR (2.05%)

Div yield 1.45%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.44

PE TTM 20.91

TSR TTM 1.28%

Mkt cap ₹1.348B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹90

8.96%

(46.82%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

3.117

Revenue₹B

—

2.812

3.042

3.392

3.031

3.117

3.242

2.60%

2.83

Revenue growth%

—

8.18

11.51

(10.65)

2.83

4.04

5.50

—

47.59

Gross margin%

—

38.78

41.43

41.81

46.16

47.59

47.68

41.81

6.11

Operating margin%

—

5.31

5.73

6.38

6.61

6.11

6.13

6.11

2.02

Net margin%

—

2.00

0.85

2.18

2.38

2.02

1.98

2.02

20.91

P/E ratio (avg)x

—

28.73

59.58

21.81

28.58

23.87

20.46

28.58

6.893

EV/EBITx

—

10.80

8.794

7.450

10.30

7.870

6.612

8.794

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

3.95

EPS₹

—

3.79

1.64

4.70

4.55

3.95

4.03

1.05%

—

(13.28)

EPS growth%

—

(56.71)

186.59

(3.11)

(13.28)

2.18

(8.19)

—

Bookvalue per sh₹

—

FCF per share₹

—

1.20

Dividend per sh₹

—

1.00

1.20

1.24

4.66%

—

1.45

Div yield (avg)%

—

0.92

1.02

1.17

0.92

1.27

1.50

1.02

—

30.40

Payout ratio%

—

26.41

61.01

25.55

26.37

30.40

30.74

26.41

—

15.92

Shares (diluted)M

—

14.82

15.69

15.74

15.85

15.92

◌15.92

1.80%

(0.42)

Buyback yield%

—

(5.86)

(0.30)

(0.74)

(0.42)

◌—

(0.58)

—

D/E ratiox

—

1.314

Enterprise value₹B

—

1.612

1.532

1.612

2.062

1.500

1.314

(1.79%)

—

LT debt₹M

—

Peers (US$13.93M)

Cap (US$)

Par Drugs and Chemical…

14.28M

10.32x

Balaxi Pharmaceuticals…

12.93M

49.20x

Krebs Biochemicals…

12.83M

—

Bioray Biotech Co., Ltd

14.30M

24.68x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

1.281

1.660

Own earn%

—

Sh yield%

1.03

0.52

Owners

Insiders/Inst%

52.19

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

1/4

Dividend streakyrs

Op margin range%

5–7

$1 testx

—

Incr. ROIC%

—

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹3.117B

2.60%

1.00×

Cost of revenue

₹1.633B

(1.31%)

0.86×

Operating expenses

₹1.293B

8.26%

1.24×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m